I have read with great interest the case report entitled "Epicardially placed implantable cardioverter-defibrillator for a child with congenital long QT syndrome" by Sugiyama et al. in the latest issue of the journal [1] . The authors well presented a case of long QT syndrome managed using implantation of an epicardial shock electrode and dose titration of beta-blocker therapy. However, some important issues should be mentioned. As compared to beta-blocker therapy with metoprolol, treatment with nadolol has been shown to significantly decrease breakthrough cardiac events in symptomatic patients [2] . Furthermore, the therapeutic efficacy of nadolol was better in patients with long QT syndrome, particularly in LQT2 [3, 4] . An implantable cardioverter-defibrillator should be considered early in the diagnosis of patients with recurrent symptoms despite receiving beta-blocker therapy, although inherent difficulties are related to much smaller body weight, body surface area, and continued growth of children. Another limitation of high-dose beta blocker therapy is that negative chronotropic effects resulted in potential device pacing attempts, which can cause atrial arrhythmias and left ventricular dysfunction with long-term atrial and ventricular Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joa Journal of Arrhythmia Fig. 1 . Direct radiography shows abdominally located active can and epicardially implanted single-coil defibrillator lead (arrow) with pacing and sensing electrodes (arrow heads) on postero-anterior (a) and left-lateral (b) projections. Epicardially implanted single-coil electrode seen on the beating heart (c).
pacing, respectively. Single-coil defibrillator lead implanted at the free wall, using an active can, might be an alternative approach (Fig. 1) . Last, device programming using high counts with initial detection, upper threshold levels 4 250 bpm with a single detection zone and maximum shock output, and features minimizing ventricular pacing should be considered in all patients with inherited arrhythmia syndromes.
